EUVIMEDEUVIMED entdecken
Crossref

Romosozumab (Evenity)

CDA-AMC

Canadian Journal of Health Technologies · 08.10.2026 · 6 (10)

DOI: 10.51731/cjht.2026.1534 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 08.10.2026. Verfasst von CDA-AMC.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

On July 16, 2026, the Formulary Management Expert Committee (FMEC) deliberated on a Request for Advice for the past romosozumab reimbursement recommendation for the treatment of osteoporosis. In this case, public drug plans were seeking clarification on the definition, interpretation, and/or meaning of “treatment naive” [from original source] that should be applied for reimbursement of romosozumab, as outlined in the reimbursement conditions from the Canadian Drug Expert Committee (CDEC) in 2021. FMEC recommends updating the initiation condition for the reimbursement of romosozumab, such that reimbursement would no longer be contingent upon the need for a patient to be treatment naive.

Zitieren

APA

CDA-AMC (2026). Romosozumab (Evenity). Canadian Journal of Health Technologies, 6(10). https://doi.org/10.51731/cjht.2026.1534

Vancouver

CDA-AMC. Romosozumab (Evenity). Canadian Journal of Health Technologies. 2026;6(10). doi:10.51731/cjht.2026.1534

BibTeX
@article{CDAAMC2026,
  author = {CDA-AMC},
  title = {Romosozumab (Evenity)},
  journal = {Canadian Journal of Health Technologies},
  year = {2026},
  volume = {6},
  number = {10},
  doi = {10.51731/cjht.2026.1534}
}
Kostenlos starten →